Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Pharma-Bio Serv (PBSV) over the last 15 years, with Q4 2025 value amounting to -$102.0.

  • Pharma-Bio Serv's Consolidated Net Income fell 10063.31% to -$102.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$110021.0, marking a year-over-year increase of 8585.16%. This contributed to the annual value of -$100463.0 for FY2025, which is 8708.07% up from last year.
  • Latest data reveals that Pharma-Bio Serv reported Consolidated Net Income of -$102.0 as of Q4 2025, which was down 10063.31% from -$213808.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Consolidated Net Income ranged from a high of $2.3 million in Q3 2021 and a low of -$4.9 million during Q4 2021
  • Moreover, its 5-year median value for Consolidated Net Income was $134366.0 (2022), whereas its average is -$33000.8.
  • Over the last 5 years, Pharma-Bio Serv's Consolidated Net Income had its largest YoY gain of 22872.01% in 2021, and its largest YoY loss of 347565.8% in 2021.
  • Over the past 5 years, Pharma-Bio Serv's Consolidated Net Income (Quarter) stood at -$4.9 million in 2021, then soared by 103.56% to $173379.0 in 2022, then tumbled by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then tumbled by 100.63% to -$102.0 in 2025.
  • Its Consolidated Net Income stands at -$102.0 for Q4 2025, versus -$213808.0 for Q3 2025 and $95353.0 for Q2 2025.